MedTrace Logo

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

NCT01952678 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 204

Last updated 2018-08-02

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with movement disorders.

Conditions

Interventions

OTHER

DaTscan™ - Non-Caucasian Participants

Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.

OTHER

DaTscan™ - Caucasian Participants

Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.

Sponsors & Collaborators

  • H2O Clinical LLC

    collaborator INDUSTRY

  • Quintiles, Inc.

    collaborator INDUSTRY

  • GE Healthcare

    lead INDUSTRY

Principal Investigators

  • Jose M Zubeldia, M.D. · GE Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01952678 on ClinicalTrials.gov